Maffezzoni Filippo, Porcelli Teresa, Karamouzis Ioannis, Quiros-Roldan Eugenia, Castelli Francesco, Mazziotti Gherardo, Giustina Andrea
Clinical Fellow, Division of Endocrinology.
Endocrinologist, Division of Endocrinology.
Eur Endocrinol. 2014 Feb;10(1):79-83. doi: 10.17925/EE.2014.10.01.79. Epub 2014 Feb 28.
The advent of highly active anti-retroviral therapy (HAART) has significantly improved the survival of human immunodeficiency virus (HIV)-infected patients transforming the HIV infection from a fatal illness into a manageable chronic disease. As the number of older HIV-infected individuals increases, several ageing-related co-morbidities including osteopenia/osteoporosis and fractures have emerged. Patients exposed to HIV infection and its treatment may develop fragility fractures with potential significant impact on quality of life and survival. However, the awareness of HIV-related skeletal fragility is still relatively low and most HIV-infected patients are not investigated for osteoporosis and treated with anti-osteoporotic drugs in daily clinical practice. This article reviews the literature data on osteoporosis and osteopenia in HIV infection, focusing on the pathophysiological, clinical and therapeutic aspects of fragility fractures.
高效抗逆转录病毒疗法(HAART)的出现显著提高了人类免疫缺陷病毒(HIV)感染患者的生存率,将HIV感染从一种致命疾病转变为一种可控制的慢性疾病。随着老年HIV感染个体数量的增加,出现了几种与衰老相关的合并症,包括骨质减少/骨质疏松和骨折。暴露于HIV感染及其治疗的患者可能会发生脆性骨折,这对生活质量和生存率有潜在的重大影响。然而,对HIV相关骨骼脆性的认识仍然相对较低,在日常临床实践中,大多数HIV感染患者没有接受骨质疏松症检查,也没有接受抗骨质疏松药物治疗。本文综述了关于HIV感染中骨质疏松和骨质减少的文献数据,重点关注脆性骨折的病理生理、临床和治疗方面。